AstraZeneca: EU approves treatment with Fasenra

(CercleFinance.com) - AstraZeneca announces that the European Union has approved Fasenra (benralizumab) as adjunctive therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a rare vasculitis that can cause multi-organ damage and be fatal without treatment.


This decision follows the positive results of the Phase III MANDARA trial, published in The New England Journal of Medicine, comparing Fasenra with mepolizumab.

Almost 60% of patients treated with Fasenra achieved remission, with 41% discontinuing oral corticosteroids (versus 26% in the comparative group).

Bernhard Hellmich, principal investigator, emphasizes the importance of this new option for reducing disabling symptoms and dependence on corticosteroids.


Copyright (c) 2024 CercleFinance.com. All rights reserved.